Objective: To investigate safety and efficacy of ZNS on motor ,non motor symptons and quality of life in advanced PD in egyptian populatiin

Background: Zonisamide (ZNS) proved some efficacy in motor symptoms of PD, however more evidence is lacking and also effects on non-motor symptoms (NMSs) and quality of life (QoL) still to be investigated. This randomized double blinded placebo-controlled crossover study investigated the effect of ZNS on motor and NMSs, and QoL in advanced PD.

Method: PD patients with Hoehn & Yahr stage ≥ 2 (“On” state) and at least 2 hours off time daily were randomized to one of three groups: ZNS 25mg, ZNS 50 mg and placebo. Groups were assessed at baseline, 1 and 3-month follow-ups using MDS-UPDRS, MDS-UDysRS, non-motor symptoms scale (NMSS) and Parkinson’s disease questionnaire-39 (PDQ-39).

Results: 69 patients were assessed for efficacy at 1-month follow-up, and 58 patients at 3-month follow-up. Both ZNS 25 and 50 mg groups showed significant improvement of total MDS-UPDRS score, part III, particularly postural tremor and part IV specifically functional impact of fluctuations and painful “Off” state dystonia, with no change of dyskinesia, NMSs, and patients’ QoL. Except for sedation, there was no significant adverse effects in both ZNS 25, and 50 mg groups compared to placebo.

Conclusion: ZNS has favorable effect on motor symptoms in patients with wearing off as adjunctive therapy with other dopaminergic drugs, with limited impact on NMSs and QoL.

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/zonisamide-in-advanced-parkinsons-disease-a-randomized-placebo-controlled-study-in-egyptian-population/